SLCO1B1 and myopathy: Although the evidence from the AKROBATS trial may not fully support the utility of genomic testing in itself in improving patient adherence [27], the concept is compelling and the use of SLCO1B1 may go one step further by not only affecting a patient’s sense of self-efficacy [32] but also reducing the probability of myopathy, an independent barrier to optimal adherence.